- PR Newswire•25 days ago
This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers. Mylan and Biocon believe that this has the potential to be the first submission of a proposed biosimilar trastuzumab in the U.S.
- PR Newswire•last monthMylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Nov. 3, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application (MAA) for insulin glargine, a long-acting insulin analog used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. This filing includes analytical, functional and pre-clinical data, as well as results from the pharmacokinetics (PK) and confirmatory efficacy/safety global clinical trial in Type 2 diabetes patients comparing Mylan's and Biocon's Insulin glargine with Lantus.
BIOCON.NS : Summary for BIOCON INR5 - Yahoo Finance
Biocon Limited (BIOCON.NS)
NSE - NSE Delayed Price. Currency in INR
Add to watchlist
|Day's Range||911.15 - 938.00|
|52 Week Range||431.00 - 1,020.00|
|PE Ratio (TTM)||16.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|